Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Domenico Magazzu"'
Autor:
Tadeusz Pienkowski, A. Lluch, Luca Gianni, Domenico Magazzu, Jose Luiz Pedrini, Brigitte Poirier, D-Y. Oh, P. Valagussa, Lajos Pusztai, Vladimir Semiglazov, Eugenia Galeota, Giampaolo Bianchini, J. de la Haba-Rodríguez, L-M Tseng, MC Liu, Yunjoo Im, Giulia Valeria Bianchi
Publikováno v:
Annals of Oncology. 26:2429-2436
Background To investigate in the NeoSphere trial the contribution of the immune system to pathologic complete response in the breast (pCRB) after neoadjuvant docetaxel with trastuzumab (TH), pertuzumab (TP), or both (THP), or monoclonal antibodies al
Autor:
Giulia Grazia, Flavio Crippa, Nicola Nicolai, Domenico Magazzu, Roberta Mortarini, Elisa Coradeschi, Elena Tassi, Maurizio Colecchia, Andrea Necchi, Patrizia Giannatempo, Andrea Anichini, Giuseppina Calareso, Roberto Salvioni, Alessandro M. Gianni, Daniele Raggi, Pinuccia Valagussa, Elena Togliardi, Biagio Paolini, Raffaella De Fato
Publikováno v:
Clinical genitourinary cancer. 14(4)
Autor:
Jose Luiz Pedrini, Seock-Ah Im, Brigitte Poirier, Young Hyuck Im, Giulia Bianchi, Ana Lluch, Luca Gianni, Mei Ching Liu, Elżbieta Starosławska, Paolo Morandi, Ling Ming Tseng, Tadeusz Pienkowski, Vichien Srimuninnimit, Pinuccia Valagussa, Juan de la Haba-Rodriguez, G. Ross, Hannah Douthwaite, Vladimir Semiglazov, V. McNally, Domenico Magazzu
Publikováno v:
The Lancet. Oncology. 17(6)
Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel af
Autor:
Begoña Bermejo, Milvia Zambetti, Isabel Alvarez, Vladimir Semiglazov, Andrew Redfern, Arrate Plazaola, Christian Dittrich, Antonio Antón, Rebecca Dent, Raffaella De Fato, Luca Gianni, Lourdes Calvo, Mauro Mansutti, Pinuccia Valagussa, Domenico Magazzu, Jose Ignacio Chacon, Ignacio Tusquets, Marc Thill, Giancarlo Bisagni, Serafin Morales, Arlene Chan
Publikováno v:
JAMA Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Importance Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not redu
Autor:
Domenico Magazzu, José Baselga, Mikhail Byakhov, Federico Vazquez, Vladimir Semiglazov, Bozhok Aa, Milvia Zambetti, Ana Lluch, Sergei Tjulandin, Jutta Steinseifer, Mauro Mansutti, Luca Gianni, Dominik Heinzmann, Pinuccia Valagussa, Belén Ojeda, Wolfgang Eiermann, Angela Moliterni, Mikhail Lichinitser, Miguel Angel Climent, Eva Ciruelos
Publikováno v:
The Lancet. Oncology. 15(6)
Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete respon
Autor:
Christian Dittrich, Serafin Morales, Andrew Redfern, Arlene Chan, Domenico Magazzu, Jose Ignacio Chacon, Giancarlo Bisagni, Vladimir Semiglazov, Arrate Plazaola, Rebecca Dent, Marc Thill, Lourdes Calvo, Pinuccia Valagussa, Begoña Bermejo, Isabel Alvarez, Milvia Zambetti, Luca Gianni, Antonio Antón, Mauro Mansutti, Ignacio Tusquets
Publikováno v:
Journal of Clinical Oncology. 34:502-502
502Background: Neoadjuvant chemotherapy regimens employing anthracyclines and taxanes have reported essentially doubled pCR rates with the addition of a taxane after anthracycline combinations. A reverse sequence did not reduce activity. nab-Paclitax
Autor:
Daniele Raggi, Pinuccia Valagussa, Alessandro M. Gianni, Giulia Grazia, Roberto Salvioni, Nicola Nicolai, Elena Togliardi, Maurizio Colecchia, Patrizia Giannatempo, Domenico Magazzu, Elisa Coradeschi, Elena Tassi, Flavio Crippa, Biagio Paolini, Andrea Anichini, Roberta Mortarini, Andrea Necchi, Giuseppina Calareso
Publikováno v:
Journal of Clinical Oncology. 34:480-480
480 Background: Prognosis of patients (pts) failing multiple chemotherapy (CT) regimens is quite dismal. CD30 is expressed and prognostic in embryonal carcinoma, hence it is a rational target for treatment. Brentuximab Vedotin (BV) is an antibody-dru
Autor:
Silvia Stagni, E. Coradeschi, Mario Catanzaro, Davide Biasoni, Andrea Necchi, Manuela Marongiu, Nicola Nicolai, Patrizia Giannatempo, Luigi Piva, Roberto Salvioni, Tullio Torelli, Daniele Raggi, Pinuccia Valagussa, Elena Farè, Massimo Maffezzini, Domenico Magazzu
Publikováno v:
Annals of Oncology. 25:iv304
Background: Transitional cell carcinoma (TCC) is the most common histology accounting for 90% of cases, and the remaining 10% are represented by pure divergent histologies (non-TCCs) such as small cell and squamous cell carcinoma, adenocarcinoma, and
Autor:
José Baselga, Gianni Bonadonna, Gabriella Mariani, Hernán Cortés-Funes, Vladimir Semiglazov, Wolfgang Eiermann, Angela Moliterni, Dolores Sabadell, Vicente Guillem, Domenico Magazzu, Belén Ojeda, Luca Gianni, Mikhail Byakhov, Tadeusz Pienkowski, Marian Colozza, Bozhok Aa, Milvia Zambetti, Ana Lluch, Pinuccia Valagussa, Mauro Mansutti
Publikováno v:
Journal of Clinical Oncology. 31:537-537
537 Background: At the time the ECTO was designed in 1996, taxanes were only indicated for patients with metastatic breast cancer. However, paclitaxel and docetaxel were still to be tested in the adjuvant setting. In addition there was relatively sca
Autor:
Maria Grazia Daidone, Patrizia Miodini, Giampaolo Bianchini, Vicente Guillem, Pinuccia Valagussa, Maurizio Callari, Biagio Paolini, Vladimir Semiglazov, Maria Luisa Carcangiu, Luca Gianni, Eleonora Di Buduo, Gabriella Mariani, Manuela Scuro, Wolfgang Eiermann, Domenico Magazzu, Vera Cappelletti, Mauro Mansutti, Milvia Zambetti, Ana Lluch, Valeria Musella
Publikováno v:
Publons
1014 Background: Predicting recurrence in operable breast cancer (BC) despite optimal chemotherapy would be relevant to new drug development and tailored treatments. Methods: A large series (n=3,154) of public Affymetrix gene-expression profiles (GEP